General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-08 | 2024-03 | 0.51 | 0.48 | -0.03 | -5.88% |
2024-01-31 | 2023-12 | 0.75 | 1 | 0.25 | 33.33% |
2023-11-08 | 2023-09 | 0.6 | 0.6 | N/A | N/A |
2023-08-02 | 2023-06 | 0.54 | 0.56 | 0.02 | 3.70% |
2023-05-10 | 2023-03 | 0.57 | 0.4 | -0.17 | -29.82% |
2023-02-08 | 2022-12 | 0.68 | 0.71 | 0.03 | 4.41% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-19 | UBS | Upgrade | Neutral | Neutral |
2023-09-07 | B of A Securities | Upgrade | Buy | Buy |
2023-07-05 | UBS | Upgrade | Sell | Neutral |
2023-05-24 | Morgan Stanley | Upgrade | Equal-Weight | |
2023-05-17 | Evercore ISI Group | Upgrade | In-Line | Outperform |
2023-05-10 | B of A Securities | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-27 | BERGWERK DOV | Officer | 96.98K | Conversion of Exercise of derivative security |
2024-03-03 | DRAPE ERIC | Officer | 77.93K | Conversion of Exercise of derivative security |
2024-03-03 | FRANCIS RICHARD D | Chief Executive Officer | 123.30K | Sale |
2024-03-03 | KALIF ELIYAHU SHARON | Chief Financial Officer | 207.53K | Conversion of Exercise of derivative security |
2024-03-04 | SABAG MARK | Officer | 382.59K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 40.29M | 303.38M | 3.59% |
2023-06-29 | Phoenix Holdings Ltd. | 33.70M | 253.79M | 3.01% |
2023-06-29 | Ion Asset Management Limited | 33.06M | 248.96M | 2.95% |
2023-06-29 | Clal Insurance Enterprises Holdings Ltd | 31.61M | 238.06M | 2.82% |
2023-06-29 | Menora Mivtachim Holdings Ltd. | 26.58M | 200.14M | 2.37% |
2023-06-29 | Lingotto Investment Management Llp | 24.21M | 182.33M | 2.16% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Fundamental Investors Inc | 6.73M | 68.62M | 0.60% |
2023-08-30 | iShares Core MSCI EAFE ETF | 6.19M | 60.43M | 0.55% |
2023-09-29 | iShares MSCI Eafe ETF | 3.52M | 35.90M | 0.31% |
2023-07-30 | New World Fund, Inc. | 2.98M | 25.03M | 0.27% |
2023-05-30 | Fidelity International Index Fund | 2.91M | 20.94M | 0.26% |
2023-09-29 | iShares MSCI Eafe Value ETF | 2.51M | 25.56M | 0.22% |
Dividend | Date |
---|---|
0.085 | 2017-11-27 |
0.085 | 2017-08-25 |
0.34 | 2017-06-01 |
0.34 | 2017-02-28 |
0.34 | 2016-12-01 |
0.34 | 2016-08-18 |
Split | Date |
---|---|
2 : 1 | 2004-07-01 |
2 : 1 | 2002-12-06 |
2 : 1 | 2000-02-23 |
2 : 1 | 1993-04-14 |
1 : 1 | 1982-08-16 |
15 is coming
settlement
settlement news
Time to sell it.
Great buy under 7
$TEVA - Lets hope we have a positive channel
https://twitter.com/shmulic12/status/1316818904874840064?s=21
Down tomorrow
Down tomorrow
$TEVA - updated chart
https://twitter.com/shmulic12/status/1278688817864560640?s=21
Teva!! Big week coming up.
They have a drug recall for Cotridin syrup was sent out to pharmacies today.
$TEVA - 12 in support
https://twitter.com/shmulic12/status/1267380297613504512?s=21
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$TEVA - Today we can confirm the signal for LONG. I am not suggesting to buy or sell, just providing a chart with few aspects.
Good luck to all
https://twitter.com/shmulic12/status/1258405843965337601?s=21